查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球急性集群性癲癇市場 - 全球產業分析、規模、份額、成長、趨勢、區域展望、預測（2023-2030）
市場調查報告書
商品編碼
1371541

全球急性集群性癲癇市場 - 全球產業分析、規模、份額、成長、趨勢、區域展望、預測（2023-2030）

Acute Repetitive Seizures Market - Global Acute Repetitive Seizures Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2030 -
出版日期: | 出版商: Fairfield Market Research | 英文 240 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

到 2030 年，全球急性癲癇群聚市場規模預計將達到 135 億美元，2023 年至 2030 年複合年增長率為 30%。

推動急性癲癇群發市場的主要趨勢之一是充分控制癲癇發作的治療差距。 目前許多患者無法獲得有效的治療，凸顯了對創新治療的需求，並促使製藥公司投資研發 (R&D)。 這不僅改善了患者護理，也代表著巨大的市場機會。

全球醫療保健產業的快速擴張也是刺激急性叢集性癲癇市場的一大趨勢。 隨著醫療保健基礎設施的發展，獲得醫療服務的機會和有效癲癇管理的需求也在增加。 該市場有望受益於全球醫療保健產業的擴張。

由於已確定的功效、多樣化的選擇以及持續的研發努力，導致配方改進和副作用減少，抗癲癇藥物 (AED) 在急性叢集性癲癇市場中經歷了顯著增長。 AED 已成為癲癇發作管理的可行選擇。

由於口服 AED 形式的便利性、患者依從性和廣泛可用性，口服給藥在急性癲癇集簇市場中變得越來越重要。 這種非侵入性方法簡化了長期癲癇管理並有助於市場成長。

醫院已成為急性發作集群市場的主要分銷管道，並已成為急性發作管理的主要中心。 同時，在以患者為中心的護理、行動醫療設備和遠距醫療趨勢的推動下，家庭護理正在發展成為一種高效、便捷的家庭護理形式。

本報告研究了全球急性癲癇集群市場，並提供了市場概述，以及按藥物類型、給藥途徑、分銷渠道、最終用途、區域和進入市場的競爭對手劃分的趨勢。我們提供趨勢、 ETC 。

目錄

第 1 章執行摘要

第二章市場概述

  • 市場定義與細分
  • 市場動態
  • 價值鏈分析
  • 波特五力分析
  • 新冠肺炎 (COVID-19) 影響分析
  • 烏克蘭和俄羅斯之間衝突的影響
  • 經濟概況
  • 杵分析

第 3 章 2018-2030 年全球急性叢集性癲癇市場展望

  • 2018-2030 年全球急性叢集性癲癇市場展望（按藥物類型、價值（十億美元）劃分）
  • 2018-2030 年全球急性癲癇群聚市場前景（按給藥途徑劃分）、價值（十億美元）
  • 2018-2030 年全球急性叢集性癲癇市場展望，按分銷管道劃分，價值（十億美元）
  • 2018-2030 年全球急性叢集性癲癇市場展望（按最終用途劃分）、價值（十億美元）
  • 2018-2030 年全球急性叢集性緝獲市場前景（按地區、價值（十億美元））

第 4 章北美急性叢集性癲癇市場展望，2018-2030

第五章歐洲急性叢集性癲癇市場展望，2018-2030

第 6 章亞太地區急性叢集性癲癇市場展望，2018-2030 年

第 7 章拉丁美洲急性叢集性癲癇市場展望，2018-2030 年

第 8 章中東與非洲急性叢集性癲癇市場展望，2018-2030 年

第九章競爭態勢

  • 分銷通路和應用程式的熱圖
  • 製造商和應用程式的熱圖
  • 2022 年公司市佔率分析
  • 競爭力儀表板
  • 公司簡介
    • Pfizer
    • Novartis
    • GlaxoSmithKline
    • Eisai Co. Ltd.
    • UCB Pharmaceuticals
    • Lundbeck
    • UCB
    • Acquestive Therapeutics
    • Marinus Pharmaceuticals
    • Takeda Pharmaceuticals
    • SK Biopharmaceuticals
    • Supernus Pharmaceuticals
    • Neurelis Inc.
    • Sage Therapeutics
    • NeuroPace

第 10 章附錄

  • 調查方法
  • 報告先決條件
  • 首字母縮寫詞和縮寫詞
簡介目錄

Global Acute Repetitive Seizures Market Projected to Reach $13.5 Billion by 2030: Rapid Growth and Key Trends Shape the Industry.

The global acute repetitive seizures market is on a trajectory of remarkable growth, with projections indicating a market size of $13.5 billion by the end of 2030, driven by a robust CAGR of 30% between 2023 and 2030. Fairfield Market Research's latest report provides a comprehensive overview of this burgeoning market, highlighting key trends, growth determinants, and the competitive landscape.

Key Trends Driving Growth in the Acute Repetitive Seizures Market

Presence of a Treatment Gap and R&D Initiatives: One of the primary trends propelling the acute repetitive seizures market is the presence of a treatment gap in achieving adequate seizure control. Many patients currently lack access to effective therapies, highlighting the demand for innovative treatments and prompting pharmaceutical companies to invest in research and development (R&D). This not only enhances patient care but also represents a significant market opportunity.

Rapidly Expanding Global Healthcare Industry: The global healthcare industry's rapid expansion is another major trend fueling the acute repetitive seizures market. As healthcare infrastructure grows, so does access to care and the demand for effective seizure management. The market is set to profit from the worldwide healthcare industry's expansion.

Dominance of Antiepileptic Drugs (AEDs): Antiepileptic drugs (AEDs) are experiencing significant growth in the acute repetitive seizures market due to their well-established efficacy, diverse options, and continuous R&D efforts leading to improved formulations and reduced side effects. AEDs have become the preferred choice for seizure management.

Growing Importance of the Oral Route: The oral route of administration is gaining prominence in the acute repetitive seizures market due to its convenience, patient compliance, and the wide availability of AEDs in oral forms. This non-invasive method simplifies long-term seizure management, contributing to its growth.

Hospitals and Home Care Settings: Hospitals are emerging as a key distribution channel in the acute repetitive seizures market, serving as primary centers for acute seizure management. In contrast, home care settings are growing due to the trend toward patient-centric care, portable medical devices, and telemedicine, making home care efficient and convenient.

Regional Insights

North America Leads the Way: North America has captured the largest market share in the acute repetitive seizures market. This dominance is attributed to its advanced healthcare infrastructure, high disease prevalence, strong R&D investments, favorable regulations, and a robust pharmaceutical industry. North America plays a dominant role in seizure management and treatment.

Asia Pacific Shows Exceptional Growth: The Asia Pacific region is poised to witness the highest CAGR in the acute repetitive seizures market. Factors such as a large patient population, increasing healthcare infrastructure, rising awareness, and expanding access to care are driving remarkable growth in this rapidly evolving market.

Competitive Landscape

The global acute repetitive seizures market is characterized by consolidation, with a select group of major players dominating the industry. These key players, including Pfizer, Novartis, GlaxoSmithKline, Eisai Co., Ltd, UCB Pharmaceuticals, Lundbeck, UCB, Aquestive Therapeutics, Marinus Pharmaceuticals, Takeda Pharmaceuticals, SK Biopharmaceuticals, Supernus Pharmaceuticals, Neurelis, Inc., Sage Therapeutics, NeuroPace, Inc and others, are actively introducing new products and expanding their distribution channels to bolster their international presence.

Table of Contents

1. Executive Summary

  • 1.1. Global Acute Repetitive Seizures Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2022
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. Covid-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Acute Repetitive Seizures Market Outlook, 2018 - 2030

  • 3.1. Global Acute Repetitive Seizures Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2030
    • 3.1.1. Key Highlights
      • 3.1.1.1. Antiepileptic Drugs (AEDs)
      • 3.1.1.2. Benzodiazepines
      • 3.1.1.3. Barbiturates
      • 3.1.1.4. Others
  • 3.2. Global Acute Repetitive Seizures Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2030
    • 3.2.1. Key Highlights
      • 3.2.1.1. Oral
      • 3.2.1.2. Intravenous
      • 3.2.1.3. Intranasal
  • 3.3. Global Acute Repetitive Seizures Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 3.3.1. Key Highlights
      • 3.3.1.1. Hospitals
      • 3.3.1.2. Specialty Clinics
      • 3.3.1.3. Retail Pharmacies
      • 3.3.1.4. Online Pharmacies
  • 3.4. Global Acute Repetitive Seizures Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
    • 3.4.1. Key Highlights Snacks
      • 3.4.1.1. Hospitals
      • 3.4.1.2. Clinics
      • 3.4.1.3. Home Care Settings
  • 3.5. Global Acute Repetitive Seizures Market Outlook, by Region, Value (US$ Bn), 2018 - 2030
    • 3.5.1. Key Highlights
      • 3.5.1.1. North America
      • 3.5.1.2. Europe
      • 3.5.1.3. Asia Pacific
      • 3.5.1.4. Latin America
      • 3.5.1.5. Middle East & Africa

4. North America Acute Repetitive Seizures Market Outlook, 2018 - 2030

  • 4.1. North America Acute Repetitive Seizures Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2030
    • 4.1.1. Key Highlights
      • 4.1.1.1. Antiepileptic Drugs (AEDs)
      • 4.1.1.2. Benzodiazepines
      • 4.1.1.3. Barbiturates
      • 4.1.1.4. Others
  • 4.2. North America Acute Repetitive Seizures Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2030
    • 4.2.1. Key Highlights
      • 4.2.1.1. Oral
      • 4.2.1.2. Intravenous
      • 4.2.1.3. Intranasal
  • 4.3. North America Acute Repetitive Seizures Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 4.3.1. Key Highlights
      • 4.3.1.1. Hospitals
      • 4.3.1.2. Specialty Clinics
      • 4.3.1.3. Retail Pharmacies
      • 4.3.1.4. Online Pharmacies
  • 4.4. North America Acute Repetitive Seizures Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
    • 4.4.1. Key Highlights
      • 4.4.1.1. Hospitals
      • 4.4.1.2. Clinics
      • 4.4.1.3. Home Care Settings
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis
  • 4.5. North America Acute Repetitive Seizures Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 4.5.1. Key Highlights
      • 4.5.1.1. U.S. Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 4.5.1.2. U.S. Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 4.5.1.3. U.S. Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 4.5.1.4. U.S. Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 4.5.1.5. Canada Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 4.5.1.6. Canada Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 4.5.1.7. Canada Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 4.5.1.8. Canada Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
    • 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Acute Repetitive Seizures Market Outlook, 2018 - 2030

  • 5.1. Europe Acute Repetitive Seizures Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2030
    • 5.1.1. Key Highlights
      • 5.1.1.1. Antiepileptic Drugs (AEDs)
      • 5.1.1.2. Benzodiazepines
      • 5.1.1.3. Barbiturates
      • 5.1.1.4. Others
  • 5.2. Europe Acute Repetitive Seizures Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2030
    • 5.2.1. Key Highlights
      • 5.2.1.1. Oral
      • 5.2.1.2. Intravenous
      • 5.2.1.3. Intranasal
  • 5.3. Europe Acute Repetitive Seizures Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 5.3.1. Key Highlights
      • 5.3.1.1. Hospitals
      • 5.3.1.2. Specialty Clinics
      • 5.3.1.3. Retail Pharmacies
      • 5.3.1.4. Online Pharmacies
  • 5.4. Europe Acute Repetitive Seizures Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
    • 5.4.1. Key Highlights
      • 5.4.1.1. Hospitals
      • 5.4.1.2. Clinics
      • 5.4.1.3. Home Care Settings
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis
  • 5.5. Europe Acute Repetitive Seizures Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 5.5.1. Key Highlights
      • 5.5.1.1. Germany Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 5.5.1.2. Germany Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 5.5.1.3. Germany Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 5.5.1.4. Germany Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 5.5.1.5. U.K. Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 5.5.1.6. U.K. Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 5.5.1.7. U.K. Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 5.5.1.8. U.K. Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 5.5.1.9. France Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 5.5.1.10. France Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 5.5.1.11. France Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 5.5.1.12. France Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 5.5.1.13. Italy Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 5.5.1.14. Italy Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 5.5.1.15. Italy Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 5.5.1.16. Italy Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 5.5.1.17. Spain Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 5.5.1.18. Spain Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 5.5.1.19. Spain Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 5.5.1.20. Spain Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 5.5.1.21. Rest of Europe Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 5.5.1.22. Rest of Europe Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 5.5.1.23. Rest of Europe Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 5.5.1.24. Rest of Europe Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Acute Repetitive Seizures Market Outlook, 2018 - 2030

  • 6.1. Asia Pacific Acute Repetitive Seizures Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2030
    • 6.1.1. Key Highlights
      • 6.1.1.1. Antiepileptic Drugs (AEDs)
      • 6.1.1.2. Benzodiazepines
      • 6.1.1.3. Barbiturates
      • 6.1.1.4. Others
  • 6.2. Asia Pacific Acute Repetitive Seizures Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2030
    • 6.2.1. Key Highlights
      • 6.2.1.1. Oral
      • 6.2.1.2. Intravenous
      • 6.2.1.3. Intranasal
  • 6.3. Asia Pacific Acute Repetitive Seizures Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 6.3.1. Key Highlights
      • 6.3.1.1. Hospitals
      • 6.3.1.2. Specialty Clinics
      • 6.3.1.3. Retail Pharmacies
      • 6.3.1.4. Online Pharmacies
  • 6.4. Asia Pacific Acute Repetitive Seizures Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
    • 6.4.1. Key Highlights
      • 6.4.1.1. Hospitals
      • 6.4.1.2. Clinics
      • 6.4.1.3. Home Care Settings
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis
  • 6.5. Asia Pacific Acute Repetitive Seizures Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 6.5.1. Key Highlights
      • 6.5.1.1. China Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 6.5.1.2. China Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 6.5.1.3. China Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 6.5.1.4. China Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 6.5.1.5. Japan Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 6.5.1.6. Japan Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 6.5.1.7. Japan Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 6.5.1.8. Japan Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 6.5.1.9. India Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 6.5.1.10. India Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 6.5.1.11. India Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 6.5.1.12. India Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 6.5.1.13. Southeast Asia Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 6.5.1.14. Southeast Asia Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 6.5.1.15. Southeast Asia Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 6.5.1.16. Southeast Asia Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 6.5.1.17. Rest of Asia Pacific Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 6.5.1.18. Rest of Asia Pacific Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 6.5.1.19. Rest of Asia Pacific Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 6.5.1.20. Rest of Asia Pacific Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Acute Repetitive Seizures Market Outlook, 2018 - 2030

  • 7.1. Latin America Acute Repetitive Seizures Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2030
    • 7.1.1. Key Highlights
      • 7.1.1.1. Antiepileptic Drugs (AEDs)
      • 7.1.1.2. Benzodiazepines
      • 7.1.1.3. Barbiturates
      • 7.1.1.4. Others
  • 7.2. Latin America Acute Repetitive Seizures Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2030
    • 7.2.1. Key Highlights
      • 7.2.1.1. Oral
      • 7.2.1.2. Intravenous
      • 7.2.1.3. Intranasal
  • 7.3. Latin America Acute Repetitive Seizures Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 7.3.1. Key Highlights
      • 7.3.1.1. Hospitals
      • 7.3.1.2. Specialty Clinics
      • 7.3.1.3. Retail Pharmacies
      • 7.3.1.4. Online Pharmacies
  • 7.4. Latin America Acute Repetitive Seizures Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
    • 7.4.1. Key Highlights
      • 7.4.1.1. Hospitals
      • 7.4.1.2. Clinics
      • 7.4.1.3. Home Care Settings
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis
  • 7.5. Latin America Acute Repetitive Seizures Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 7.5.1. Key Highlights
      • 7.5.1.1. Brazil Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 7.5.1.2. Brazil Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 7.5.1.3. Brazil Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 7.5.1.4. Brazil Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 7.5.1.5. Mexico Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 7.5.1.6. Mexico Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 7.5.1.7. Mexico Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 7.5.1.8. Mexico Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 7.5.1.9. Rest of Latin America Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 7.5.1.10. Rest of Latin America Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 7.5.1.11. Rest of Latin America Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 7.5.1.12. Rest of Latin America Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Acute Repetitive Seizures Market Outlook, 2018 - 2030

  • 8.1. Middle East & Africa Acute Repetitive Seizures Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2030
    • 8.1.1. Key Highlights
      • 8.1.1.1. Antiepileptic Drugs (AEDs)
      • 8.1.1.2. Benzodiazepines
      • 8.1.1.3. Barbiturates
      • 8.1.1.4. Others
  • 8.2. Middle East & Africa Acute Repetitive Seizures Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2030
    • 8.2.1. Key Highlights
      • 8.2.1.1. Oral
      • 8.2.1.2. Intravenous
      • 8.2.1.3. Intranasal
  • 8.3. Middle East & Africa Acute Repetitive Seizures Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 8.3.1. Key Highlights
      • 8.3.1.1. Hospitals
      • 8.3.1.2. Specialty Clinics
      • 8.3.1.3. Retail Pharmacies
      • 8.3.1.4. Online Pharmacies
  • 8.4. Middle East & Africa Acute Repetitive Seizures Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
    • 8.4.1. Key Highlights
      • 8.4.1.1. Hospitals
      • 8.4.1.2. Clinics
      • 8.4.1.3. Home Care Settings
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis
  • 8.5. Middle East & Africa Acute Repetitive Seizures Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 8.5.1. Key Highlights
      • 8.5.1.1. GCC Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 8.5.1.2. GCC Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 8.5.1.3. GCC Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 8.5.1.4. GCC Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 8.5.1.5. South Africa Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 8.5.1.6. South Africa Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 8.5.1.7. South Africa Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 8.5.1.8. South Africa Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
      • 8.5.1.9. Rest of Middle East & Africa Acute Repetitive Seizures Market by Drug Type, Value (US$ Bn), 2018 - 2030
      • 8.5.1.10. Rest of Middle East & Africa Acute Repetitive Seizures Market Route of Administration, Value (US$ Bn), 2018 - 2030
      • 8.5.1.11. Rest of Middle East & Africa Acute Repetitive Seizures Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 8.5.1.12. Rest of Middle East & Africa Acute Repetitive Seizures Market End Use, Value (US$ Bn), 2018 - 2030
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Distribution Channel vs Application Heatmap
  • 9.2. Manufacturer vs Application Heatmap
  • 9.3. Company Market Share Analysis, 2022
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Pfizer
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Product Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Novartis
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Product Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. GlaxoSmithKline
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Product Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. Eisai Co. Ltd.
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Product Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. UCB Pharmaceuticals
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Product Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. Lundbeck
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Product Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. UCB
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Product Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. Acquestive Therapeutics
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Product Portfolio
      • 9.5.8.3. Business Strategies and Development
    • 9.5.9. Marinus Pharmaceuticals
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Product Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development
    • 9.5.10. Takeda Pharmaceuticals
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Product Portfolio
      • 9.5.10.3. Financial Overview
      • 9.5.10.4. Business Strategies and Development
    • 9.5.11. SK Biopharmaceuticals
      • 9.5.11.1. Company Overview
      • 9.5.11.2. Product Portfolio
      • 9.5.11.3. Financial Overview
      • 9.5.11.4. Business Strategies and Development
    • 9.5.12. Supernus Pharmaceuticals
      • 9.5.12.1. Company Overview
      • 9.5.12.2. Product Portfolio
      • 9.5.12.3. Financial Overview
      • 9.5.12.4. Business Strategies and Development
    • 9.5.13. Neurelis Inc.
      • 9.5.13.1. Company Overview
      • 9.5.13.2. Product Portfolio
      • 9.5.13.3. Financial Overview
      • 9.5.13.4. Business Strategies and Development
    • 9.5.14. Sage Therapeutics
      • 9.5.14.1. Company Overview
      • 9.5.14.2. Product Portfolio
      • 9.5.14.3. Financial Overview
      • 9.5.14.4. Business Strategies and Development
    • 9.5.15. NeuroPace
      • 9.5.15.1. Company Overview
      • 9.5.15.2. Product Portfolio
      • 9.5.15.3. Financial Overview
      • 9.5.15.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations